RecruitingPhase 2NCT07126262
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Studying Hypochondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Intervention
- Vosoritide(drug)
- Enrollment
- 60 target
- Eligibility
- All sexes
- Timeline
- 2025 – 2028
Study locations (26)
- Phoenix Children's Hospital - Thomas Campus (Main), Phoenix, Arizona, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Benioff Children's Hospital - Oakland, Oakland, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- University of Minneasota Masonic Children's Hospital, Minneapolis, Minnesota, United States
- University of Missouri, Columbia, Missouri, United States
- Cook Children's Endocrinology, Fort Worth, Texas, United States
- Children's Wisconsin - Fox Valley Hospital, Neenah, Wisconsin, United States
- Children's Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia
- Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
- Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France
- Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, Rhone-Alps, France
- Uniklinik Köln, Cologne, North Rhine-Westphalia, Germany
- +11 more locations on ClinicalTrials.gov
Collaborators
ICON Clinical Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07126262 on ClinicalTrials.govOther trials for Hypochondroplasia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07393373Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- ENROLLING BY INVITATIONPHASE3NCT07073014Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaBioMarin Pharmaceutical
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaBioMarin Pharmaceutical
- RECRUITINGNCT06410976Prospective Clinical Assessment Study in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- RECRUITINGNCT06212947A Multicenter Multinational Observational Study of Children With HypochondroplasiaBioMarin Pharmaceutical